<p>The most common adverse reactions ( &ge;20%) with single-agent use of Nab-Paclitaxel in metastatic&nbsp;breast cancer&nbsp;are&nbsp;alopecia,&nbsp;neutropenia, sensory&nbsp;neuropathy, abnormal&nbsp;ECG, fatigue/asthenia, myalgia/arthralgia, AST elevation, alkaline phosphatase elevation,&nbsp;anemia, nausea, infections, and diarrhea.<br />
<br />
The most common adverse reactions ( &ge;20%) of Nab-Paclitaxel in combination with carboplatin for&nbsp;non-small cell lung cancer&nbsp;are anemia, neutropenia,&nbsp;thrombocytopenia, alopecia,&nbsp;peripheral neuropathy, nausea, and fatigue.<br />
<br />
The most common serious adverse reactions of Nab-Paclitaxel in combination with carboplatin for non-small cell lung cancer are anemia (4%) and&nbsp;pneumonia&nbsp;(3%).<br />
<br />
The most common adverse reactions resulting in permanent discontinuation of Nab-Paclitaxel are neutropenia (3%), thrombocytopenia (3%), and peripheral neuropathy (1%).<br />
<br />
The most common adverse reactions resulting in dose reduction of Nab-Paclitaxel are neutropenia (24%), thrombocytopenia (13%), and anemia (6%).<br />
<br />
The most common adverse reactions leading to withholding or delay in Nab-Paclitaxel dosing are neutropenia (41%), thrombocytopenia (30%), and anemia (16%).</p>